Monte Rosa Therapeutics Inc

NASDAQ GLUE

Download Data

Monte Rosa Therapeutics Inc Current Assets to Total Assets Ratio 2 year CAGR for the quarter ending March 31, 2024: -10.23%

Monte Rosa Therapeutics Inc Current Assets to Total Assets Ratio 2 year CAGR is -10.23% for the quarter ending March 31, 2024, a -7.51% change year over year. The current assets to total assets ratio measures the proportion of a company's current assets in relation to its total assets. It is calculated by dividing current assets by total assets. This ratio indicates the percentage of a company's total assets that are in the form of current assets, such as cash, receivables, and inventory. It provides insights into the company's liquidity and the extent to which its assets are readily convertible to cash in the short term. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Monte Rosa Therapeutics Inc Current Assets to Total Assets Ratio for the quarter ending March 31, 2023 was 0.78, a -15.93% change year over year.
  • Monte Rosa Therapeutics Inc Current Assets to Total Assets Ratio for the quarter ending March 31, 2022 was 0.93, a -2.61% change year over year.
  • Monte Rosa Therapeutics Inc Current Assets to Total Assets Ratio for the quarter ending March 31, 2021 was 0.95.
NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO Dr. Markus Warmuth M.D.
IPO Date June 24, 2021
Location United States
Headquarters 645 Summer Street, Boston, MA, United States, 02210
Employees 130
Sector Healthcare
Industry Biotechnology
Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Similar companies

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

STOK

Stoke Therapeutics Inc

NA

NA

GRCL

Gracell Biotechnologies Inc.

NA

NA

THRX

Theseus Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email